University of Thessaly (UTH)
Ανακάλυψη αναστολέων για την πρωτεΐνη TNF-α σαν ενώσεις οδηγούς για φάρμακα έναντι της ρευματοειδoύς αρθρίτιδας
Abstract
dc:descriptionThe subject of this thesis is the discovery of novel small-molecule inhibitors of Tumor Necrosis Factor (TNF). TNF has been related to autoimmune diseases such as psoriasis, Crohn’s disease, Alzheimer’s disease and plays a pivotal role in Rheumatoid Arthritis pathogenesis. Anti-TNF therapy is used for diseases such as ankylotic spondylitis, rheumatoid and psoriatic arthritis, psoriasis, inflammatory bowel disease etc. SPD304 is a small molecule that inhibits the activity of TNF by interacting with the protein trimer, promoting protein detrimerization and thus an inactivated dimer is formed in complex with SPD304. SPD304 is toxic and for this reason it can not be utilized as a drug for anti-TNF therapy but only as a basis for the discovery of new small-molecule inhibitors that prevent protein trimerization. Thus, the development of small-molecule TNF inhibitors remains a desirable goal.The subject of RAlead project was the discovery of small-molecule TNF inhibitors and for this purpose a series of SPD304 analogs was designed and synthesized aiming at the elimination of toxicity and the enhancement of activity. Additionally, commercially available compounds that have risen from docking studies as well as compounds designed on the basis of the results of the binding assays were studied.For the evaluation of the potential inhibitors the dissociation constant (Kd) was measured with fluorescence spectroscopy. The binding mechanism was studied with Isothermal Titration Calorimetry (ITC). The binding mode of SPD304 to TNF protein used for the binding assays, was studied with X-ray crystallography. For all the assays above, TNF was expressed as a GST-protein in E-coli cells and purified according to the protocol that was developed. A serious problem that has risen during this study was the low aqueous solubility of the studied compounds. Techniques on solubility enhancement were studied and a solubilization protocol for small molecules was developed. This protocol was adapted to the binding assay in order to be compatible with the assay and the protein. Except for in vitro biochemical assays such techniques can be a powerful tool in crystallization of protein complexes with small molecules.A series of 86 SPD304 analogues were studied together with 60 potential inhibitors derived from docking studies. The majority of these compounds was not soluble enough for the measurent of dissociation constant. With solubility enhancement most of them became sufficiently soluble and the binding studies took place. During solubility studies different cosolvents (DMSO, PEG3350) and other additives (β-cyclodextrin) were tested and it was shown that PEG3350 is more effective than DMSO for moderately insoluble compounds while β-cyclodextrin is efficient even for extremely insoluble compounds. Furthermore, factors that affect solubility such as dissolution time, initial state of the compound and filtering of the sample before the measurement were studied.Binding studies showed that 30 compounds were more active than SPD304 (<5μM) and 20 more had similar activity with SPD304 (~5μM). Some of them had also decreased toxicity. The percentage of the compounds that were initially insoluble in aqueous solutions was calculated at 76% and after the solubility studies it decreased to 20%. This means that finally 80% of the compounds was soluble enough for the binding assays.An aqueous solubility prediction model was developed (Novamechanics) which was based on the above results. This predictive Quantitative Structure Property Relationship model categorizes soluble from insoluble compounds. It aims at solubility prediction of small-molecule candidate inhibitors of TNF in aqueous solutions with 5% DMSO. The simplicity of the proposed method makes it broadly applicable to virtual screening and data mining in order to identify soluble molecules.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Mettou, Anthoula
- Μέττου, Ανθούλα
Subjects
dc:subject × 15- Αναστολείς TNF-α
- SPD304
- Βιοενεργότητα
- Διαλυτότητα μικρών φαρμακοφόρων μορίων
- Ενίσχυση υδατικής διαλυτότητας
- Κρυσταλλογραφία πρωτεϊνών με ακτίνες-Χ
- Inhibitors of TNF-α
- Bioactivity
- Solubility of small drug molecules
- Aqueous solubility enhancement
- X-ray protein crystallography
- Φυσικές Επιστήμες
- Βιολογία
- Natural Sciences
- Biological Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/41794